cortagen: the Khavinson neuroprotective tetrapeptide

cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro, developed in the 1990s at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. it is the short synthetic analog of cortexin, a polypeptide extract from calf cerebral cortex that has been used in Russian neurology since the 1980s. cortagen sits in the broader Khavinson family of short bioregulator peptides that also includes epitalon, thymalin, prostagen, and a long catalogue of organ-specific tetra- and tripeptides.

what is cortagen?

cortagen (sometimes spelled cortagene in older sources) is a four-amino-acid synthetic peptide. its sequence is Ala-Glu-Asp-Pro (alanine-glutamic acid-aspartic acid-proline), often abbreviated AEDP. it was designed as the minimum active fragment of cortexin and is one of dozens of short bioregulator peptides produced by Khavinson's institute over several decades.

the Khavinson program has a distinctive structure: starting from a tissue-derived polypeptide extract (here, calf cerebral cortex yielding cortexin), the team identifies a short synthetic peptide they propose carries the activity of the larger preparation. the same approach produced epitalon (Ala-Glu-Asp-Gly) from pineal-gland epithalamin, thymalin from thymus extract, and prostagen from prostate extract [1]. cortagen is the cortex member of that family. it is not an endogenous human peptide; it is a designed sequence intended to capture cortex-extract activity in a single defined molecule.

cortexin itself, the parent preparation, has been registered in Russia as a CNS therapeutic since the 1980s for conditions including post-stroke recovery, traumatic brain injury, cognitive disorders, and pediatric encephalopathy. cortagen is a more recent synthetic derivative, and unlike cortexin it does not have a formal registration as a Russian therapeutic to our knowledge. it is sold and studied as a research peptide.

how does it work?

the Khavinson group proposes that short peptides like cortagen act as transcriptional regulators: they penetrate the nuclear membrane, bind to specific DNA sequences, and modulate gene expression in a tissue-specific manner. the proposed mechanism remains controversial outside the Russian literature, has not been independently validated by major Western groups, and is not consistent with conventional molecular-biology priors about how short oligopeptides interact with chromatin.

Khavinson and colleagues have published computational docking and in vitro binding studies that they interpret as showing direct binding of short peptides to specific DNA promoters and to histone-related sequences, with downstream upregulation of tissue-specific gene sets [2]. the rodent behavioral and biochemical effects of cortagen reported in the same body of work (improved cognition in stress models, modulation of cortical neurotransmitter levels, neuroprotection in ischemia models) are reproducible within the group but have not been replicated by independent Western laboratories. the honest framing is that the downstream effects are real in the published preclinical literature, while the proposed mechanism is the unresolved and contested part.

a less exotic interpretation of the cortagen literature is that the peptide acts at cell-surface receptors or as a substrate for endogenous proteolysis, releasing free amino acids that have non-specific effects. the mainstream literature on dietary di- and tripeptides supports the existence of PEPT1/PEPT2 oligopeptide transporters that move short peptides across membranes, which is compatible with intracellular delivery without invoking direct DNA binding [3]. this alternative mechanism is consistent with the observed biology and does not require any unusual chromatin chemistry.

what does the evidence show?

the cortagen evidence base is essentially confined to Russian preclinical and small clinical literature. there are no large multicentre randomized controlled trials, no FDA-registered trials, and no peer-reviewed Western publications of the kind that would support clinical claims. the parent preparation cortexin has a longer published track record, again largely in Russian-language sources.

the cortagen preclinical literature describes effects on cortical neuron survival in cell-culture ischemia models, on behavioral endpoints in rodent stress-exposure paradigms, and on biochemical markers of oxidative stress in rodent brain tissue. Khavinson and colleagues have summarized this body of work in several review articles, including the 2014 review of short peptide biological activity that catalogues the proposed indications across the Khavinson family [1]. the publications are mostly in Russian journals or in Russian-affiliated English-language journals; replication outside that ecosystem is sparse.

the clinical evidence for cortexin (the parent preparation) is more developed and includes Russian observational studies in post-stroke recovery, neonatal hypoxic-ischemic encephalopathy, and adult cognitive impairment [4]. these reports support a registered Russian indication but do not meet modern Western standards for evidence-based recommendation: most are open-label, single-center, and lack the placebo controls and pre-registered endpoints that Western regulators require. cortagen specifically has not been the subject of registration-quality clinical studies.

a separate strand of the Khavinson literature focuses on aging-related endpoints and telomere biology, anchored by the work on epitalon. cortagen has been included in some of these studies as a control or as an organ-specific bioregulator, but its primary positioning in the published work is neuroprotection and cortical-neuron physiology rather than longevity [5].

regulatory status

cortagen is not approved for medical use in the United States, the European Union, the United Kingdom, or any major Western regulatory jurisdiction. cortexin, the polypeptide preparation that cortagen mimics, has historically been registered in Russia as a CNS therapeutic. cortagen itself is sold internationally only as a research peptide.

the absence of Western regulatory recognition is the dominant fact about cortagen's status. there are no INDs in the US, no Marketing Authorisation Applications in the EU, and no clinical trial registrations in major Western trial databases. material sold by peptide vendors outside Russia is labeled as research-use-only and is not intended for human administration.

the World Anti-Doping Agency does not list cortagen by name but the broad WADA-prohibition language around peptide hormones, growth factors, related substances, and mimetics covers a wide swath of synthetic peptides and would apply. athletes in WADA-tested sport should treat cortagen and related Khavinson peptides as falling within that prohibition.

safety profile

there are no controlled human safety datasets for cortagen meeting modern Western standards. Russian-language preclinical and small clinical work has reported low acute toxicity and a generally benign side-effect profile, consistent with the broader Khavinson safety pattern, but the depth of this safety characterization is much less than what would be required for Western regulatory approval.

the Russian literature characterizes cortagen as well tolerated at the doses used in animal studies and small clinical observations, with no characteristic acute toxicity syndrome. the broader Khavinson family has been used in Russian clinical practice for decades without obvious safety signals being reported, but the published toxicology data are limited and not in the public databases that Western regulators rely on.

the most useful safety frame is therefore mechanistic. as a short synthetic tetrapeptide, cortagen is unlikely to produce immediate small-molecule-style organ toxicity, because the amount of any free amino acid released by proteolysis is small. the more relevant concerns are longer-term chronic-administration questions, immunogenicity at injection sites, and the consequences of any actual gene-expression modulation in non-target tissues if the proposed transcriptional mechanism is real. none of these have been formally characterized in trials of the standard required for Western approval.

where it fits in peptide therapy

cortagen sits in the Khavinson short-peptide family, which is best understood as a parallel research tradition with its own theoretical framework, its own evidence standards, and its own pharmaceutical ecosystem. the family is interesting as a set of well-characterized short synthetic sequences with reproducible preclinical effects; the integration of that body of work with mainstream pharmacology remains unresolved.

the natural comparison within the Khavinson family is epitalon (Ala-Glu-Asp-Gly), the pineal-axis member that is the most-discussed Khavinson peptide internationally because of its association with telomere and aging-related claims. cortagen shares epitalon's structure (four residues, similar charge profile) and the same proposed transcriptional mechanism, but it is targeted at cortical biology rather than the pineal axis.

outside the Khavinson tradition, cortagen does not have a direct mainstream analogue. the closest comparisons are other neuroprotection-positioned synthetic peptides like selank and semax, both originally Soviet/Russian developments, both with anxiolytic and cognitive positioning, and both more widely studied in modern Russian and Eastern European literature. cerebrolysin, a different porcine-brain-derived peptide preparation, is registered in many countries (though not in the US) for stroke recovery and represents another Eastern-European neuroprotection therapeutic tradition.

for a broader map of how Khavinson peptides relate to mainstream research peptides, the underlying biology is covered in our free peptides and your body module, and the FDA-approved versus research distinction is summarized in our peptide approval guide.